Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Phenoxodiol: isoflavone analog with antineoplastic activity.

Toni K Choueiri¹, Robert Wesolowski, Tarek M Mekhail

¹Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R-35, Cleveland, OH 44195, USA. choueit@ccf.org

Current Oncology Reports

|March 2, 2006

Summary

Phenoxodiol, a novel oncology drug, induces apoptosis to combat cancer by degrading antiapoptotic proteins. Ongoing studies explore its potential in treating various cancers, including ovarian and prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Oncotype DX Risk Categorization and Receipt of Chemotherapy on Survival Outcomes Among Patients with Small Node-Negative HR+ Breast Cancer.

The oncologist·2026

Same author

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions.

Frontiers in oncology·2026

Same author

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

Nature communications·2026

Same author

Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single Institution.

Cancer control : journal of the Moffitt Cancer Center·2026

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Phenoxodiol is a synthetic analog of genistein, acting as a multi-signal transduction regulator.
It targets antiapoptotic proteins, crucial in chemoresistance, via apoptosis induction.
Preclinical studies indicate broad anticancer potential against solid and hematologic malignancies.

Purpose of the Study:

To evaluate the efficacy and safety of phenoxodiol in cancer treatment.
To explore its role in chemotherapy-resistant cancers.
To define optimal therapeutic strategies for phenoxodiol.

Main Methods:

Preclinical investigations of anticancer activity.
Early-phase clinical trials in ovarian and prostate cancer patients.

Related Experiment Videos

Assessment of toxicity and antitumor activity.

Main Results:

Preclinical studies demonstrated promising anticancer activity.
Early clinical trials in ovarian cancer showed minimal toxicity and minor antitumor effects.
Phenoxodiol is being actively investigated in hormone-refractory prostate cancer.

Conclusions:

Phenoxodiol shows potential as a novel anticancer agent targeting multiple signaling pathways.
Further research is required to establish its optimal clinical application and efficacy in various cancer types.
Ongoing studies aim to define its role in treating resistant and advanced cancers.